VALARIE CLARK: Open Payments
NPI 1285288951 · LAKE CHARLES, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,125 in 134 payments from 16 companies in 2025. Trend: 2023 $2,110 · 2024 $1,953 · 2025 $2,125
Food & beverage: $2,045Education: $80
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 19 | $360 |
| Teva Pharmaceuticals USA, Inc. | 18 | $343 |
| Otsuka America Pharmaceutical, Inc. | 24 | $287 |
| ABBVIE INC. | 25 | $282 |
| Alkermes, Inc. | 13 | $177 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $162 |
| Janssen Pharmaceuticals, Inc | 8 | $156 |
| Indivior Inc. | 3 | $74 |
| E.R. Squibb & Sons, L.L.C. | 3 | $60 |
| Axsome Therapeutics, Inc. | 3 | $60 |
Products named: INGREZZA, VRAYLAR, REXULTI, CAPLYTA, ARISTADA, UZEDY, INVEGA SUSTENNA, AUSTEDO XR.
Industry payments across LA — which companies pay providers there.
